@article{ref1,
title="Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication",
journal="Drugs and therapy perspectives",
year="2022",
author="Balasundaram, M.K. and Singh, A.",
volume="38",
number="2",
pages="77-83",
abstract="Viloxazine (SPN-812), an age-old antidepressant, has recently been approved by the US FDA for the treatment of attention-deficit hyperactivity disorder (ADHD) in children aged 6-17 years, at a dose range of 100-400 mg/day. Viloxazine acts primarily by norepinephrine reuptake inhibition and may also modulate the serotonergic system. The efficacy of viloxazine for the treatment of ADHD in children aged 6-17 years has been demonstrated in a series of short-term clinical trials. The most common adverse events include somnolence and gastrointestinal upset, while the FDA has issued a black-box warning regarding suicidal ideation or behavior. This article summarizes the information regarding viloxazine based on previously published narrative reviews, preclinical studies, and blinded controlled clinical trials. © 2022, The Author(s), under exclusive licence to Springer Nature Switzerland AG.<p /><p>Language: en</p>",
language="en",
issn="1172-0360",
doi="10.1007/s40267-022-00892-z",
url="http://dx.doi.org/10.1007/s40267-022-00892-z"
}